Benlysta (belimumab) prior authorization
Customize your policy alerts
Sign up for all mediviewcurative policy alerts
Know when mediviewcurative releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity criteria and prior authorization requirements for Benlysta (belimumab) for members of Curative Health Plan when used for FDA‑approved indications (systemic lupus erythematosus and lupus nephritis). Applies to prescribers submitting requests for coverage.
No material clinical or coverage changes in this revision.
Coverage Criteria for Benlysta (belimumab)
Benlysta (belimumab) must not be used in combination with another biologic agent or with Lupkynis; requests documenting combination therapy will not meet the coverage criteria and may be denied. Chart notes or prescriber statements documenting severe active central nervous system (CNS) lupus are also exclusionary for consideration under these criteria.
These combination and major-constraint exclusions apply to both initial and continued therapy determinations for systemic lupus erythematosus and lupus nephritis; the policy language explicitly requires absence of documentation showing combination use or severe active CNS disease for approval of either initial (approval duration 6 months) or continued (approval duration 12 months) therapy.
For both initial and continued therapy requests, submit contemporaneous clinical documentation demonstrating the diagnosis and treatment history. Initial SLE and LN requests require chart notes within the past 120 days; continued therapy requests require documentation within the past 12 months.
Prior therapy documentation must show current treatment with hydroxychloroquine (or a documented contraindication) and trial and intolerance or inadequate response to at least one immunosuppressive agent (e.g., mycophenolate, azathioprine, methotrexate, tacrolimus, cyclosporine). For lupus nephritis, documentation of optimized standard therapy (including hydroxychloroquine plus mycophenolate or cyclophosphamide) is required; adults may also need documented inadequate response or intolerance to Gazvya where specified.
Specialist involvement is expected: the prescriber should be a relevant specialist (e.g., rheumatology or nephrology) or provide documentation of consultation with a specialist. For LN, if proteinuria is present, documentation that the patient is starting or is on a renin‑angiotensin‑aldosterone system (RAAS) inhibitor is also required.
Requests lacking the required prior therapies, diagnostic confirmation (serologies for SLE or kidney biopsy for LN when feasible), evidence of clinical benefit for continuation, or documentation of specialist involvement are at risk for denial as not meeting medical necessity.
Provider Actions, Prior Authorization & Documentation
Prior authorization and billing
Prior authorization is required for Benlysta (belimumab). Submit clinical documentation demonstrating the patient meets the applicable initial or continued therapy criteria. For medical billing use HCPCS code J0490 (belimumab), 1 unit = 10 mg.
- Include indication (SLE or lupus nephritis) and which criteria set is being met.
- Specify patient age (must be ≥5 years) and prescriber specialty or consult.
- For LN requests, include biopsy confirmation when feasible or documented contraindication to biopsy.
Prior therapy requirements (step therapy)
Document trials of and intolerance or inadequate response to required prior therapies before initiating Benlysta: for SLE, hydroxychloroquine plus at least one immunosuppressive agent (e.g., mycophenolate, azathioprine, methotrexate, tacrolimus, cyclosporine); for LN, optimized standard therapy including hydroxychloroquine and mycophenolate or cyclophosphamide, and for certain adult LN patients a trial of Gazvya is required or documented intolerance/contraindication to Gazvya.
- SLE: current treatment with hydroxychloroquine (or documented contraindication) AND intolerance/failure to ≥1 immunosuppressive therapy.
- LN: optimized standard therapy (hydroxychloroquine + mycophenolate or cyclophosphamide); for nephrotic-range proteinuria, trial of a calcineurin inhibitor or documented reason it's inappropriate.
- Adults with LN (≥18 years): inadequate response to Gazvya or intolerance/FDA contraindication to Gazvya when applicable.
Required supporting documentation
Provide recent clinical and diagnostic documentation supporting the indication: chart notes showing active disease within the required timeframe, serologies or complement levels (ANA, anti‑dsDNA, C3/C4), biopsy reports for lupus nephritis when available, and documentation of prior therapies and responses.
- Initial requests: chart notes documenting active disease within the past 120 days; continued requests: within the past 12 months.
- Laboratory evidence: positive ANA or anti‑dsDNA or low complement (C3/C4) as applicable.
- LN: percutaneous kidney biopsy report unless contraindicated; proteinuria measurements and RAAS inhibitor use if proteinuria present.
- Document current or prior use, intolerance, or failure of hydroxychloroquine and immunosuppressive agents (and Gazvya for eligible adults with LN).
Triggers for potential denial — missing documentation or timeframe failures
Requests may be denied if required documentation or timeframe criteria are missing—examples include absence of recent chart notes confirming active disease, missing serologies or biopsy confirmation for LN, or lack of documented prior therapy trials or specialist involvement.
- No chart notes showing active SLE within 120 days (initial) or within 12 months (continued).
- No biopsy confirmation of LN when feasible or missing proteinuria/response data required for continuation.
- No documentation of trials/intolerance/failure of required therapies (hydroxychloroquine, immunosuppressives, Gazvya when required).
- Documentation that Benlysta is being used in combination with another biologic or with Lupkynis, or documentation of severe active CNS lupus.
Billing and Coding
| J0490 | belimumab (Benlysta), 1 unit = 10 mg |
Key Definitions
Background
Benlysta (belimumab) is a biologic therapy indicated as adjunctive treatment for systemic lupus erythematosus and for lupus nephritis when used in accordance with the policy’s medical necessity criteria. The policy requires objective diagnostic evidence (positive ANA or anti‑dsDNA or low complement for SLE; percutaneous kidney biopsy for LN unless contraindicated) and adherence to standard-of-care background therapy before Benlysta is approved.
Age and treatment context are specified: coverage considerations apply to patients aged 5 years and older, and approvals are time-limited with initial authorizations typically for 6 months and continued approvals for 12 months provided documentation of clinical benefit or renal response thresholds where applicable.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.